EMBARK: A Phase 3b, Open-label, Single-arm, Study to Evaluate the Long-term Safety and Efficacy of Aducanumab in Eligible Participants with Alzheimer’s Disease

Released by

Biogen

1 of 20

Previous slideNext slide

Creator

Biogen

Category

Healthcare

Published

2020

DownloadShareAsk AI

Slides

Open in new tab

Open in new tab

Open in new tab

Open in new tab

Open in new tab

Open in new tab

Open in new tab

Open in new tab

Open in new tab

Open in new tab

Open in new tab

Open in new tab

Open in new tab

Open in new tab

Open in new tab

Open in new tab

Open in new tab

Open in new tab

Open in new tab

Transcriptions

#1#2#3#4#5#6#7#8#9#10#11#12#13#14#15#16#17#18#19

Download to PowerPoint

Download presentation as an editable powerpoint.

Download